X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse IPCA Labs with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs TEVA PHARMA (Israel) - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 IPCA LABS   TEVA PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
TEVA PHARMA
Dec-13
IPCA LABS/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs6952,873-   
Low Rs4002,495-   
Sales per share (Unadj.) Rs260.21,648.6-  
Earnings per share (Unadj.) Rs19.0103.0-  
Cash flow per share (Unadj.) Rs33.1236.2-  
Dividends per share (Unadj.) Rs1.0090.15-  
Dividend yield (eoy) %0.23.4 5.4%  
Book value per share (Unadj.) Rs213.01,831.3-  
Shares outstanding (eoy) m126.20848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.11.6 129.3%   
Avg P/E ratio x28.926.1 110.8%  
P/CF ratio (eoy) x16.611.4 145.8%  
Price / Book Value ratio x2.61.5 175.4%  
Dividend payout %5.387.5 6.0%   
Avg Mkt Cap Rs m69,1202,276,015 3.0%   
No. of employees `00013.344.9 29.5%   
Total wages/salary Rs m7,3590-   
Avg. sales/employee Rs Th2,477.431,104.9 8.0%   
Avg. wages/employee Rs Th555.20-   
Avg. net profit/employee Rs Th180.61,943.1 9.3%   
INCOME DATA
Net Sales Rs m32,8361,398,009 2.3%  
Other income Rs m4180-   
Total revenues Rs m33,2541,398,009 2.4%   
Gross profit Rs m4,505382,846 1.2%  
Depreciation Rs m1,777113,002 1.6%   
Interest Rs m24027,459 0.9%   
Profit before tax Rs m2,905242,384 1.2%   
Minority Interest Rs m01,101 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-159,112 0.0%   
Tax Rs m511-2,959 -17.3%   
Profit after tax Rs m2,39487,333 2.7%  
Gross profit margin %13.727.4 50.1%  
Effective tax rate %17.6-1.2 -1,440.9%   
Net profit margin %7.36.2 116.7%  
BALANCE SHEET DATA
Current assets Rs m19,455944,210 2.1%   
Current liabilities Rs m10,076823,431 1.2%   
Net working cap to sales %28.68.6 330.6%  
Current ratio x1.91.1 168.4%  
Inventory Days Days9891 107.8%  
Debtors Days Days6796 69.8%  
Net fixed assets Rs m20,260456,621 4.4%   
Share capital Rs m2523,441 7.3%   
"Free" reserves Rs m26,6330-   
Net worth Rs m26,8861,552,923 1.7%   
Long term debt Rs m2,340714,833 0.3%   
Total assets Rs m41,1733,194,900 1.3%  
Interest coverage x13.19.8 133.3%   
Debt to equity ratio x0.10.5 18.9%  
Sales to assets ratio x0.80.4 182.3%   
Return on assets %6.43.6 178.1%  
Return on equity %8.95.6 158.3%  
Return on capital %10.84.9 218.2%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Net fx Rs m10,7590-   
CASH FLOW
From Operations Rs m3,411222,770 1.5%  
From Investments Rs m-1,354-78,937 1.7%  
From Financial Activity Rs m-1,304-267,228 0.5%  
Net Cashflow Rs m753-123,394 -0.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 68.82 Rs / USD

Compare IPCA LABS With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare IPCA LABS With: PLETHICO PHARMA  LUPIN  FDC LTD.  PANACEA BIOTECH  SUVEN LIFESCIENCES  



Today's Market

Sensex Ends 305 Points Lower; FMCG and Finance Stocks Witness Huge Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day deep in the red.

Related Views On News

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound (Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock (Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend (The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock (The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jul 22, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - FRESENIUS KABI ONCO. COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS